Skip to main content

Advertisement

SpringerLink
Log in

Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma

  • Original Paper
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Purpose

Patients with medulloblastoma are exposed to ototoxic treatments including radiation therapy and platinum chemotherapy. The favorable toxicity profile of carboplatin led us to substitute this chemotherapeutic agent for cisplatin in the HIT-1991, HIT-MED-1999, and HIT-2000 chemotherapy protocols. We retrospectively investigated its consequences in terms of overall survival and ototoxicity rates.

Methods

Twenty-four medulloblastoma patients were treated according to HIT protocols with carboplatin substitution between April 1999 and June 2006. Nineteen (79%) patients had adequate baseline and post-treatment audiological data. Mean age at diagnosis was 9.3 (range 3.5–18.9) years with a mean follow-up time of 30.8 (8.1–111.3) months. Patients received a mean carboplatin cumulative dose of 2,131 (830–4312) mg/m2.

Results

Twenty-three patients were alive at the time of assessment. Hearing loss greater than 20 dB was observed in two (10.5%) of 19 patients. Both had grade 2 ototoxicity according to Brock’s scale. There were no significant differences between the patients’ baseline and post-treatment audiograms at any frequency. The observed hearing loss was significantly correlated to younger age at diagnosis and cumulative carboplatin dose (p < 0.05).

Conclusions

The encouraging overall survival and low hearing loss rates in this medulloblastoma patient cohort suggest that protocols containing carboplatin may offer a viable alternative to standard cisplatin protocols and warrant further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Huang E, Teh BS, Strother DR, Davis QG, Chiu JK, Lu HH, Carpenter LS, Mai WY, Chintagumpala MM, South M, Grant WH, Butler EB, Woo SY (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52:599–605

    Article  PubMed  Google Scholar 

  2. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, Muraszko K, Rorke LB, Wara WM, Cohen BH, Boyett JM (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 17:2127

    CAS  PubMed  Google Scholar 

  3. Kortmann R, Kühl J, Timmermann B, Calaminus G, Dieckmann K, Wurm R, Sörensen N, Urban C, Gö B, Bamberg M (2001) Aktuelle und zukünftige strategien in der interdisziplinären therapie von medulloblastomen, supratentoriellen PNET und intrakraniellen keimzelltumoren im kindesalter. Strahlenther Onkol 177:447–461

    Article  CAS  PubMed  Google Scholar 

  4. Schrama JG, Holtkamp MJ, Baars JW, Schornagel JH, Rodenhuis S (2003) Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer 88:1831–1838

    Article  CAS  PubMed  Google Scholar 

  5. Rose SR, Danish RK, Kearney NS, Schreiber RE, Lustig RH, Burghen GA, Hudson MM (2005) ACTH deficiency in childhood cancer survivors. Pediatr Blood Cancer 45:808–813

    Article  PubMed  Google Scholar 

  6. Heikens J, Michiels EM, Behrendt H, Endert E, Bakker PJ, Fliers E (1998) Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer 34:1592–1597

    Article  CAS  PubMed  Google Scholar 

  7. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE (2004) Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 5:399–408

    Article  PubMed  Google Scholar 

  8. Rueckriegel SM, Blankenburg F, Henze G, Baqué H, Driever PH (2009) Loss of fine motor function correlates with ataxia and decline of cognition in cerebellar tumor survivors. Pediatr Blood Cancer 53:424–431

    Article  PubMed  Google Scholar 

  9. Packer RJ (1999) Childhood medulloblastoma: progress and future challenges. Brain Dev 21:75–81

    Article  CAS  PubMed  Google Scholar 

  10. Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649–655

    Article  PubMed  Google Scholar 

  11. Knight KRG, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596

    Article  PubMed  Google Scholar 

  12. Stern JW, Bunin N (2002) Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med Pediatr Oncol 39:163–167

    Article  PubMed  Google Scholar 

  13. Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 10:1663–1682

    CAS  PubMed  Google Scholar 

  14. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300

    Article  CAS  PubMed  Google Scholar 

  15. Ilveskoski I, Saarinen UM, Wiklund T, Perkkiö M, Salmi TT, Lanning M, Mäkipernaa A, Pihko H (1996) Ototoxicity in children with malignant brain tumors treated with the “8 in 1” chemotherapy protocol. Med Pediatr Oncol 27:26–31

    Article  CAS  PubMed  Google Scholar 

  16. Kortmann RD, Kuhl J, Timmermann B, Mittler U, Urban C, Budach V, Richter E, Willich N, Flentje M, Berthold F, Slavc I, Wolff J, Meisner C, Wiestler O, Sorensen N, Warmuth-Metz M, Bamberg M (2001) Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of German prospective randomised trial HIT′91. Cancer Radiothér 5:197–198

    Google Scholar 

  17. Goetz C, Müller-Weirich B, Poellinger B (2004) Kindliche Hirntumoren. In: Tonn J (ed) Hirntumoren und primäre Tumoren des Rückenmarks, 2nd ed. Zuckschwerdt, München [i.e.] Germering. Wien, New York, pp 89–97

  18. Montaguti M, Brandolini C, Ferri GG, Hatzopoulos S, Prete A, Pession A (2002) Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital 22:14–18

    CAS  PubMed  Google Scholar 

  19. De Lauretis A, De Capua B, Barbieri MT, Bellussi L, Passàli D (1999) ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand Audiol 28:139–143

    Article  PubMed  Google Scholar 

  20. Packer RJ, Cogen P, Vezina G, Rorke LB (1999) Medulloblastoma: clinical and biologic aspects. Neuro Oncol 1:232–250

    CAS  PubMed  Google Scholar 

  21. Tabori U, Sung L, Hukin J, Laperriere N, Crooks B, Carret A, Silva M, Odame I, Mpofu C, Strother D, Wilson B, Samson Y, Bouffet E, Consortium CPBT (2005) Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management. Cancer 103:1874–1880

    Article  PubMed  Google Scholar 

  22. Carey JP, Cooper T, Jallo GI, Carson BS, Guarnieri M (2005) Ototoxicity of carboplatin delivered locally in a monkey brainstem. Int J Toxicol 24:443–449

    Article  CAS  PubMed  Google Scholar 

  23. Knight KR, Kraemer DF, Winter C, Neuwelt EA (2007) Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25:1190–1195

    Article  CAS  PubMed  Google Scholar 

  24. Bess FH, Dodd-Murphy J, Parker RA (1998) Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 19:339–354

    Article  CAS  PubMed  Google Scholar 

  25. Williams GB, Kun LE, Thompson JW, Gould HJ, Stocks RMS (2005) Hearing loss as a late complication of radiotherapy in children with brain tumors. Ann Otol Rhinol Laryngol 114:328–331

    PubMed  Google Scholar 

  26. Lokich J, Anderson N (1998) Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol 9:13–21

    Article  CAS  PubMed  Google Scholar 

  27. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, Mulne L, Boyett J, D’Angio G, Wechsler-Jentzsch K (1994) Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81:690–698

    Article  CAS  PubMed  Google Scholar 

  28. Low WK, Toh ST, Wee J, Fook-Chong SMC, Wang DY (2006) Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 24:1904–1909

    Article  PubMed  Google Scholar 

  29. Jereczek-Fossa BA, Zarowski A, Milani F, Orecchia R (2003) Radiotherapy-induced ear toxicity. Cancer Treat Rev 29:417–430

    Article  PubMed  Google Scholar 

  30. Kretschmar CS, Warren MP, Lavally BL, Dyer S, Tarbell NJ (1990) Ototoxicity of preradiation cisplatin for children with central nervous system tumors. J Clin Oncol 8:1191–1198

    CAS  PubMed  Google Scholar 

  31. Rood BR, Macdonald TJ, Packer RJ (2004) Current treatment of medulloblastoma: recent advances and future challenges. Semin Oncol 31:666–675

    Article  PubMed  Google Scholar 

  32. Fischer P (2004) Embryonal tumors. In: Gupta N, Banerjee A, Haas-Kogan D (eds) Pediatric CNS tumors, 1st edn. Springer, Berlin, pp 84–100

    Google Scholar 

  33. Berg AL, Spitzer JB, Garvin JH (1999) Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope 109:1806–1814

    Article  CAS  PubMed  Google Scholar 

  34. Murakami T, Inoue S, Sasaki K, Fujimoto T (1990) Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin. Sel Cancer Ther 6:145–151

    CAS  PubMed  Google Scholar 

  35. Fossati P, Ricardi U, Orecchia R (2009) Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy. Cancer Treat Rev 35:79–96

    Article  CAS  PubMed  Google Scholar 

  36. Mulhern RK, Palmer SL, Reddick WE, Glass JO, Kun LE, Taylor J, Langston J, Gajjar A (2001) Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol 19:472–479

    CAS  PubMed  Google Scholar 

  37. Rueckriegel SM, Driever PH, Blankenburg F, Lüdemann L, Henze G, Bruhn H (2010) Differences in supratentorial damage of white matter in pediatric survivors of posterior fossa tumors with and without adjuvant treatment as detected by magnetic resonance diffusion tensor imaging. Int J Radiat Oncol Biol Phys 76:859–866

    Article  PubMed  Google Scholar 

  38. Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE, Moeller MP (2004) The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 130:556–562

    Article  PubMed  Google Scholar 

  39. Pittman AL, Stelmachowicz PG (2000) Perception of voiceless fricatives by normal-hearing and hearing-impaired children and adults. J Speech Lang Hear Res 43:1389–1401

    CAS  PubMed  Google Scholar 

  40. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML (2007) Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children’s Oncology Group. Pediatrics 120:e1229–e1236

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Special thanks to Astrid Burneleit for managing the medical records, to Frederik Grosse, Jörn Kiselev, and Dian S. Bright for their critical reading of this manuscript, and to Andrea Stroux for the statistics advice.

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany

    Lindy Musial-Bright, Rüdiger Fengler, Günter Henze & Pablo Hernáiz Driever

Authors
  1. Lindy Musial-Bright
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rüdiger Fengler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Günter Henze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pablo Hernáiz Driever
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pablo Hernáiz Driever.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Musial-Bright, L., Fengler, R., Henze, G. et al. Carboplatin and ototoxicity: hearing loss rates among survivors of childhood medulloblastoma. Childs Nerv Syst 27, 407–413 (2011). https://doi.org/10.1007/s00381-010-1300-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-010-1300-1

Keywords

Search

Navigation